Wall Street Zen downgraded shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
A number of other brokerages have also recently issued reports on ALGS. HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Jefferies Financial Group initiated coverage on shares of Aligos Therapeutics in a report on Monday, November 9th. They issued a “strong-buy” rating on the stock. Finally, Weiss Ratings lowered shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aligos Therapeutics has an average rating of “Moderate Buy” and an average price target of $38.50.
View Our Latest Stock Report on Aligos Therapeutics
Aligos Therapeutics Stock Performance
Aligos Therapeutics stock opened at $1.66 on Friday. Aligos Therapeutics has a 1 year low of $1.58 and a 1 year high of $13.69. The business has a 50-day moving average of $4.85 and a 200-day moving average of $5.99.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($2.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.19. The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $4.85 million. Aligos Therapeutics had a negative net margin of 197.01% and a negative return on equity of 206.30%. On average, analysts anticipate that Aligos Therapeutics will post -6.61 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aligos Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its holdings in Aligos Therapeutics by 17.6% during the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock worth $746,000 after purchasing an additional 15,006 shares in the last quarter. SummitTX Capital L.P. lifted its holdings in shares of Aligos Therapeutics by 6.7% in the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Aligos Therapeutics by 1,652.8% in the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.
Aligos Therapeutics Company Profile
Aligos Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases. The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.
Further Reading
- Five stocks we like better than Aligos Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
